Duloxetin STADA (Duloxetine)
Serotonin-norepinephrine reuptake inhibitor for stress urinary incontinence
Duloxetin STADA contains the active substance duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used to treat stress urinary incontinence (SUI) in women. It strengthens the muscles that prevent urine leakage during physical activities such as coughing, sneezing, laughing, or exercising. This guide provides comprehensive information about dosage, side effects, drug interactions, and important safety considerations based on international clinical guidelines.
Quick Facts
Key Takeaways
- Duloxetin STADA (duloxetine) is an SNRI prescribed for stress urinary incontinence in women, working by strengthening the urethral sphincter muscles
- The standard dose is 40 mg twice daily; treatment often starts at 20 mg twice daily for the first two weeks, then increases to the full dose
- Must not be combined with MAO inhibitors, fluvoxamine, ciprofloxacin, or enoxacin due to risk of serious interactions
- Treatment effectiveness is enhanced when combined with pelvic floor muscle exercises (Kegel exercises)
- Never stop duloxetine abruptly — gradual dose reduction over at least two weeks is recommended to avoid withdrawal symptoms
What Is Duloxetin STADA and What Is It Used For?
Duloxetin STADA belongs to a class of medications known as serotonin-norepinephrine reuptake inhibitors (SNRIs). The active ingredient, duloxetine, works by increasing the levels of two important neurotransmitters — serotonin and norepinephrine — in the nervous system. These chemical messengers play a crucial role in regulating various bodily functions, including the control of urinary sphincter muscles.
Stress urinary incontinence (SUI) is a medical condition characterized by involuntary urine leakage during physical exertion or activities that place pressure on the bladder. Common triggers include laughing, coughing, sneezing, heavy lifting, and exercise. SUI is estimated to affect approximately 20–40% of women worldwide, with prevalence increasing with age, particularly after childbirth and menopause. The condition can significantly impact quality of life, leading to social embarrassment and avoidance of physical activities.
Duloxetine is believed to exert its therapeutic effect in SUI by enhancing the activity of the pudendal nerve, which controls the external urethral sphincter. By increasing serotonin and norepinephrine levels at the level of the sacral spinal cord, the medication strengthens the contractile force of the striated urethral sphincter during the storage phase of the micturition cycle. This mechanism effectively reduces the frequency and severity of urine leakage episodes during physical stress.
Clinical studies have demonstrated that duloxetine can reduce incontinence episode frequency by approximately 50–60% compared to baseline, with some patients achieving complete continence. The effectiveness of duloxetine is significantly enhanced when combined with pelvic floor muscle training (PFMT), also known as Kegel exercises. The European Association of Urology (EAU) guidelines recommend this combined approach as an optimal treatment strategy for moderate to severe SUI.
Duloxetine is also approved under different brand names for treating major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia. You should not take more than one product containing duloxetine at the same time. If you are already taking duloxetine for another condition, inform your healthcare provider.
What Should You Know Before Taking Duloxetin STADA?
Contraindications
There are several situations in which Duloxetin STADA must not be used. You should not take this medication if you are allergic to duloxetine or any of the excipients listed in the composition section of this guide. Additionally, the following conditions represent absolute contraindications:
- Liver disease: Duloxetine is extensively metabolized in the liver. Patients with hepatic impairment may have significantly elevated drug concentrations, increasing the risk of adverse effects
- Severe kidney disease: Patients with severe renal impairment (creatinine clearance <30 mL/min) should not use duloxetine due to impaired drug elimination
- MAO inhibitor use: You must not take duloxetine if you are currently taking, or have taken within the past 14 days, a monoamine oxidase inhibitor (see Drug Interactions section)
- Concurrent use of fluvoxamine, ciprofloxacin, or enoxacin: These medications are potent CYP1A2 inhibitors and can dramatically increase duloxetine blood levels, leading to toxicity
If you have high blood pressure or heart disease, your doctor will need to evaluate whether Duloxetin STADA is appropriate for you. Cardiovascular monitoring may be necessary during treatment, as duloxetine can cause modest increases in blood pressure.
Warnings and Precautions
Before starting treatment with Duloxetin STADA, inform your healthcare provider about all medical conditions and medications. Special caution is warranted in the following circumstances:
- Seizure history: Duloxetine should be used with caution in patients with a history of seizures or epilepsy, as it may lower the seizure threshold
- Bipolar disorder or mania: SNRI medications may trigger manic episodes in susceptible individuals. Inform your doctor if you have a history of bipolar disorder
- Glaucoma: Duloxetine may increase intraocular pressure. Patients with narrow-angle glaucoma or elevated eye pressure should be closely monitored
- Bleeding disorders: SNRIs can affect platelet function and increase the risk of bleeding, particularly when combined with anticoagulants or antiplatelet agents
- Low sodium levels (hyponatremia): Particularly in elderly patients or those taking diuretics, duloxetine may cause a syndrome of inappropriate antidiuretic hormone secretion (SIADH)
- Kidney disease: Even moderate renal impairment may require dose adjustments or enhanced monitoring
Contact your doctor immediately if you experience a combination of the following symptoms: restlessness, hallucinations, loss of coordination, rapid heartbeat, elevated body temperature, rapid blood pressure changes, overactive reflexes, diarrhea, nausea, or vomiting. These may be signs of serotonin syndrome, a potentially life-threatening condition that can occur when duloxetine is combined with other serotonergic medications. In its most severe form, serotonin syndrome can resemble neuroleptic malignant syndrome (NMS), with symptoms including fever, rapid heartbeat, sweating, severe muscle rigidity, and confusion.
Although Duloxetin STADA is not indicated for depression treatment, duloxetine is also used as an antidepressant. Patients, particularly those under 25 years of age, may experience worsening of depressive symptoms or emergence of suicidal thoughts, especially during the first weeks of treatment. Seek immediate medical attention if you experience thoughts of self-harm or suicide. Inform a family member or close friend so they can help monitor for behavioral changes.
Use in children and adolescents: Duloxetin STADA should not be used in patients under 18 years of age. Clinical data indicate an increased risk of suicidal behavior, hostility, and aggression in this age group when treated with SNRI/SSRI medications. Long-term effects on growth, maturation, and cognitive development have not been adequately studied.
Sexual dysfunction: SNRI medications, including duloxetine, may cause sexual side effects such as decreased libido, difficulty achieving orgasm, or erectile dysfunction. In some cases, these symptoms may persist after discontinuation of treatment. Discuss any concerns with your healthcare provider.
Restlessness and akathisia: Duloxetin STADA may cause a feeling of restlessness and difficulty sitting or standing still. If you experience this, inform your doctor promptly as dose adjustment may be necessary.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, consult your healthcare provider before using Duloxetin STADA. The decision to use duloxetine during pregnancy requires careful evaluation of potential benefits versus risks to the developing fetus.
Available data from the first trimester of pregnancy do not suggest an overall increased risk of major birth defects. However, use of duloxetine during the second half of pregnancy may be associated with an increased risk of premature birth (approximately 6 additional preterm births per 100 women), predominantly between weeks 35 and 36 of gestation.
If duloxetine is taken near delivery, the newborn may experience withdrawal symptoms including muscle limpness, tremors, feeding difficulties, respiratory problems, and seizures. These symptoms typically appear at birth or within the first few days of life. Additionally, there is an increased risk of a serious condition called persistent pulmonary hypertension of the newborn (PPHN), which causes rapid breathing and bluish skin coloration, usually within 24 hours of birth.
There is also an increased risk of severe postpartum vaginal bleeding in women taking duloxetine at the time of delivery, particularly in those with a history of bleeding disorders. Inform your midwife or obstetrician about your medication use.
Breastfeeding: Duloxetine is excreted in breast milk. The use of Duloxetin STADA during breastfeeding is not recommended. Consult your healthcare provider to discuss alternative options.
Driving and Operating Machinery
Duloxetin STADA may cause drowsiness, dizziness, or blurred vision. Do not drive or operate heavy machinery until you are confident that your ability to perform these activities safely is not affected. Individual responses to the medication vary, and you should assess your own fitness before engaging in activities requiring alertness.
How Does Duloxetin STADA Interact with Other Drugs?
Drug interactions can alter how duloxetine works or increase the risk of serious side effects. It is essential to provide your healthcare provider with a complete list of all medications, supplements, and herbal products you use. The following sections outline the most clinically significant interactions.
Major Interactions (Avoid Combination)
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| MAO inhibitors (e.g., moclobemide, linezolid) | Life-threatening serotonin syndrome | Wait 14 days after stopping an MAO inhibitor; wait 5 days after stopping duloxetine before starting an MAO inhibitor |
| Fluvoxamine | Up to 6-fold increase in duloxetine levels (CYP1A2 inhibition) | Combination is contraindicated |
| Ciprofloxacin / Enoxacin | Significant increase in duloxetine levels (CYP1A2 inhibition) | Combination is contraindicated |
Moderate Interactions (Use with Caution)
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| SSRIs (e.g., paroxetine, fluoxetine) | Increased serotonin syndrome risk | Monitor for serotonergic symptoms; avoid if possible |
| Triptans (migraine medications) | Increased serotonin syndrome risk | Use with caution; monitor closely |
| Tramadol | Serotonin syndrome risk; lowered seizure threshold | Avoid combination if possible |
| Tricyclic antidepressants (e.g., amitriptyline, clomipramine) | Increased serotonin levels; elevated tricyclic levels | Monitor drug levels and symptoms |
| St. John's wort (Hypericum perforatum) | Increased serotonin syndrome risk | Avoid concurrent use |
| Anticoagulants / Antiplatelets (e.g., warfarin, aspirin) | Increased bleeding risk | Monitor for signs of bleeding; INR monitoring for warfarin |
| Benzodiazepines / CNS depressants | Enhanced sedation, drowsiness | Use lowest effective doses; monitor for excess sedation |
Food, Drink, and Alcohol
Duloxetin STADA can be taken with or without food. However, you should exercise caution with alcohol consumption during treatment. The combination of duloxetine and alcohol may increase the risk of liver damage and can exacerbate common side effects such as drowsiness and dizziness. The European Medicines Agency (EMA) advises patients to limit or avoid alcohol while taking duloxetine-containing products.
What Is the Correct Dosage of Duloxetin STADA?
Always take Duloxetin STADA exactly as prescribed by your healthcare provider. The dosage may vary based on individual clinical response and tolerability. Do not alter your dose or stop treatment without consulting your doctor first.
Adults
Standard Dosing for Stress Urinary Incontinence
- Starting dose: 20 mg twice daily (morning and late afternoon/evening) for the first 2 weeks
- Maintenance dose: 40 mg twice daily (morning and late afternoon/evening)
- Administration: Swallow capsules whole with a glass of water. Do not crush, chew, or open the capsules
- Timing: Take at the same times each day for optimal adherence
The gradual dose escalation approach helps minimize the occurrence of nausea, which is one of the most common side effects and a frequent reason for early treatment discontinuation. Clinical trials have shown that this titration strategy reduces the incidence of nausea by approximately 30% compared to immediate full-dose initiation.
Your doctor will periodically reassess the need for continued treatment. For stress urinary incontinence, the effectiveness of duloxetine is enhanced when combined with pelvic floor muscle training. A structured exercise programme supervised by a physiotherapist is recommended alongside medication for optimal outcomes.
Children and Adolescents
Duloxetin STADA is not recommended for use in children and adolescents under 18 years of age. Safety and efficacy have not been established in this population, and there are concerns about an increased risk of suicidal behavior in young patients treated with SNRI medications.
Elderly Patients
No dose adjustment is routinely required for elderly patients based on age alone. However, caution is advised as older adults may be more susceptible to certain side effects, including hyponatremia (low sodium levels), falls, and orthostatic hypotension (dizziness upon standing). Renal function should be assessed before initiating treatment, as age-related decline in kidney function may affect drug clearance.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for the one you missed. Never take more duloxetine capsules per day than prescribed by your doctor.
Overdose
If you suspect an overdose, contact your local emergency services or poison control center immediately. Symptoms of duloxetine overdose may include drowsiness, coma, serotonin syndrome (euphoria, restlessness, fever, muscle stiffness, sweating), seizures, vomiting, and rapid heartbeat. There is no specific antidote for duloxetine overdose; treatment is supportive and symptomatic.
Stopping Treatment
Do not stop taking Duloxetin STADA abruptly, even if you feel better. Sudden discontinuation may cause withdrawal symptoms (discontinuation syndrome), which can include:
- Dizziness and vertigo
- Tingling sensations or electric shock-like feelings, especially in the head ("brain zaps")
- Sleep disturbances including vivid dreams, nightmares, and insomnia
- Fatigue and drowsiness
- Restlessness, agitation, or anxiety
- Nausea and vomiting
- Tremors and headache
- Muscle pain, irritability, and diarrhea
- Excessive sweating
These symptoms are typically mild and resolve within a few days to two weeks. To minimize the risk of withdrawal symptoms, your doctor will usually taper the dose gradually over at least two weeks. If you experience troublesome discontinuation symptoms, consult your healthcare provider for guidance on managing the withdrawal process.
What Are the Side Effects of Duloxetin STADA?
Like all medicines, Duloxetin STADA can cause side effects, although not everyone experiences them. Most side effects are mild to moderate in severity and typically resolve within a short period as your body adjusts to the medication. The following classification is based on standard pharmacovigilance frequency categories.
Very Common
Affects more than 1 in 10 people
- Nausea
- Dry mouth
- Constipation
- Fatigue
Common
Affects up to 1 in 10 people
- Decreased appetite
- Insomnia, agitation, decreased libido, anxiety
- Headache, dizziness, feeling sluggish, drowsiness, tremor, numbness/tingling
- Blurred vision
- Vertigo
- Elevated blood pressure, flushing
- Diarrhea, abdominal pain, vomiting, heartburn/indigestion
- Increased sweating
- Weakness, chills
Uncommon
Affects up to 1 in 100 people
- Throat inflammation, hoarseness
- Allergic reactions, decreased thyroid function
- Dehydration, teeth grinding, disorientation, difficulty reaching orgasm
- Dilated pupils, visual disturbances, dry eyes, tinnitus
- Palpitations, rapid/irregular heartbeat, fainting
- Yawning, nosebleed
- Liver inflammation, difficulty swallowing, flatulence
- Rash, hives, night sweats, increased bruising
- Muscle pain, tension, twitching, jaw cramps
- Difficulty urinating, painful urination, frequent urination
- Abnormal vaginal bleeding, weight changes
Rare to Very Rare
Affects fewer than 1 in 1,000 people
- Severe allergic reactions (angioedema, anaphylaxis)
- Hyponatremia (low sodium) — especially in elderly; symptoms include confusion, weakness, seizures
- Suicidal behavior, mania, aggression
- Serotonin syndrome, seizures, akathisia (restlessness)
- Glaucoma (increased eye pressure)
- Orthostatic hypotension, cold fingers/toes
- Liver problems, jaundice
- Stevens-Johnson syndrome, photosensitivity
- Urinary retention
- Abnormal menstruation, galactorrhea
- Severe postpartum hemorrhage
- Stress cardiomyopathy (Takotsubo syndrome)
- Cutaneous vasculitis
Duloxetine may also cause laboratory changes that you may not notice, including elevated liver enzymes and changes in blood levels of potassium, creatine phosphokinase, glucose, or cholesterol. Your healthcare provider may order periodic blood tests to monitor for these changes.
Contact your doctor or seek emergency care immediately if you experience signs of a severe allergic reaction (difficulty breathing, facial/throat swelling), symptoms of serotonin syndrome (see Warnings section), severe abdominal pain with yellowing of the skin or eyes (possible liver damage), or any thoughts of self-harm.
How Should You Store Duloxetin STADA?
Proper storage of medications is essential to maintain their effectiveness and safety. Duloxetin STADA should be stored according to the following guidelines:
- Temperature: No special temperature requirements — store at room temperature
- Packaging: Keep in the original blister packaging to protect from moisture
- Safety: Store out of sight and reach of children
- Expiry: Do not use after the expiry date (EXP) shown on the blister and carton. The expiry date refers to the last day of that month
Do not dispose of medications via household waste or wastewater drainage systems. Return unused or expired medicines to your local pharmacy for safe disposal. This helps protect the environment and prevents accidental exposure.
What Does Duloxetin STADA Contain?
Understanding the composition of your medication can help identify potential allergens and intolerances. Duloxetin STADA capsules are formulated as hard gastro-resistant capsules containing fine pellets coated with an enteric coating that resists dissolution in the acidic stomach environment, ensuring the active ingredient is released in the intestine for optimal absorption.
Active Ingredient
- 20 mg capsules: Each capsule contains 20 mg duloxetine (as duloxetine hydrochloride)
- 40 mg capsules: Each capsule contains 40 mg duloxetine (as duloxetine hydrochloride)
Excipients (Inactive Ingredients)
Capsule contents: Hypromellose, hypromellose acetate succinate, sucrose, sugar spheres (sucrose, maize starch), talc, titanium dioxide (E171), hydroxypropyl cellulose.
Capsule shell: Gelatin, titanium dioxide (E171), indigo carmine (E132), black iron oxide (E172), yellow iron oxide (E172), red iron oxide (E172) (40 mg capsule only).
Capsule Appearance
- 20 mg: Blue body and blue cap, filled with off-white gastro-resistant pellets
- 40 mg: Orange body and blue cap, filled with off-white gastro-resistant pellets
Pack Sizes
Duloxetin STADA capsules are supplied in PVC/PCTFE/PVC/Al blisters:
- 20 mg: Packs of 28, 56, and 98 capsules
- 40 mg: Packs of 28, 56, 98, and 140 capsules
Not all pack sizes may be marketed in your country.
Duloxetin STADA contains sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Frequently Asked Questions About Duloxetin STADA
Duloxetin STADA contains duloxetine and is primarily prescribed for the treatment of stress urinary incontinence (SUI) in women. SUI causes involuntary urine leakage during physical activities such as laughing, coughing, sneezing, lifting heavy objects, or exercising. Duloxetine works by increasing serotonin and norepinephrine levels in the nervous system, which strengthens the muscles that control urine release. The active ingredient duloxetine is also used in other branded products for treating depression, generalized anxiety disorder, and diabetic neuropathic pain.
The most common side effects (affecting more than 1 in 10 people) include nausea, dry mouth, constipation, and fatigue. Common side effects (up to 1 in 10 people) include headache, dizziness, drowsiness, decreased appetite, insomnia, anxiety, increased sweating, and elevated blood pressure. Most side effects are mild to moderate in severity and tend to improve within the first few weeks of treatment. If nausea is bothersome, starting at a lower dose (20 mg twice daily) for two weeks can help reduce this effect.
Duloxetin STADA should only be used during pregnancy after careful evaluation of benefits versus risks by your doctor. There is no evidence of increased birth defects in the first trimester, but use during the second half of pregnancy may increase the risk of premature birth. If taken near delivery, the newborn may experience symptoms such as muscle limpness, tremors, breathing difficulties, feeding problems, or seizures. There is also an increased risk of postpartum hemorrhage and a serious newborn condition called persistent pulmonary hypertension (PPHN). Always discuss your medication use with your midwife or obstetrician.
Clinical improvement in stress urinary incontinence symptoms typically begins within 2 to 4 weeks of starting duloxetine at the recommended dose. The full therapeutic benefit may take several weeks to develop. For optimal results, duloxetine should be combined with pelvic floor muscle exercises (Kegel exercises), as the combination has been shown to be more effective than either treatment alone. Your doctor will assess your response and adjust the treatment plan accordingly.
Suddenly stopping duloxetine can cause discontinuation symptoms (withdrawal effects), especially if you have been taking the medication for more than one week. Common withdrawal symptoms include dizziness, tingling or electric shock-like sensations (particularly in the head), sleep disturbances, vivid dreams or nightmares, fatigue, restlessness, anxiety, nausea, tremors, headache, muscle pain, irritability, diarrhea, and excessive sweating. To prevent these symptoms, your doctor will typically reduce your dose gradually over at least two weeks before stopping completely.
You should be cautious with alcohol consumption while taking Duloxetin STADA. The combination of duloxetine and alcohol may increase the risk of liver damage and can worsen side effects such as drowsiness, dizziness, and impaired judgment. While moderate alcohol use may not be strictly prohibited, it is advisable to limit your intake and discuss your alcohol consumption with your healthcare provider before starting treatment.
References and Sources
This article is based on peer-reviewed medical literature and international clinical guidelines. All medical claims are supported by Level 1A evidence where available.
- European Medicines Agency (EMA). Duloxetine — Summary of Product Characteristics. EMA Product Database. Updated 2024.
- U.S. Food and Drug Administration (FDA). Duloxetine Hydrochloride — Prescribing Information. FDA Drug Database. Updated 2024.
- National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. NICE Guideline NG123. Updated 2024.
- European Association of Urology (EAU). Guidelines on Urinary Incontinence in Adults. EAU Guidelines. 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023.
- British National Formulary (BNF). Duloxetine. BNF Online. Accessed January 2026.
- Mariappan P, Alhasso A, Ballantyne Z, et al. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol. 2007;51(1):67-74.
- Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol. 2004;104(3):511-519.
- Ghoniem GM, Van Leeuwen JS, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol. 2005;173(5):1647-1653.
- Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
Editorial Team
This article has been written and reviewed by qualified medical professionals following international clinical guidelines and the GRADE evidence framework.
iMedic Medical Editorial Team — Specialists in clinical pharmacology and evidence-based medicine with extensive experience in patient-facing medical communication.
iMedic Medical Review Board — Independent panel of board-certified physicians who verify medical accuracy, currency, and adherence to international guidelines (EMA, FDA, WHO, NICE).
Disclosure: The editorial team has no conflicts of interest. iMedic does not accept pharmaceutical company sponsorship or advertising. All content is independently produced and funded.